Biomea Fusion, Inc. (BMEA) Stock Score, Valuation & Financial Research

Biomea Fusion, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BMEA

Biomea Fusion, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.25. These figures are a research snapshot, not a buy or sell recommendation.

What Biomea Fusion, Inc. does

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Biomea Fusion is a clinical-stage biotechnology company that has not yet generated any revenue from product sales. Its business model is currently focused on the research and development of oral small molecule therapies for the treatment of diabetes and obesity, relying on capital raises to fund its ongoing clinical trials and operations.

Products and services

The company is developing a pipeline of oral small molecule drug candidates, primarily icovamenib for metabolic disorders and BMF-650 (GLP-131) for obesity.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and manage data collection. Source
Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its drug candidates for clinical use. Source

Business strengths to evaluate

Proprietary platform for developing oral small molecule covalent inhibitors Source

Business risks and research considerations

History of operating losses and no revenue generation Source
Dependence on the success of clinical-stage product candidates Source
Substantial dilution from future capital raises Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BMEA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 1.25
Market capitalization:: 90.37M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -32.54M
Free cash flow:: USD -70.37M
Cash:: USD 34.82M
Total debt:: USD 877K
EPS:: USD -0.50

What stands out

Free cash flow is USD -70.37M, negative for the stored period.
The balance sheet shows USD 34.82M of cash versus USD 877K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 33.95M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BMEA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can BMEA fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is BMEA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for BMEA to reach sustainable profitability?
What does the current corporate distress warning mean for the reliability or interpretation of BMEA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BMEA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.